TR200101790T2 - Yayılgan olmayan in vivo topik uygulamalar için geliştirilmiş formül - Google Patents

Yayılgan olmayan in vivo topik uygulamalar için geliştirilmiş formül

Info

Publication number
TR200101790T2
TR200101790T2 TR2001/01790T TR200101790T TR200101790T2 TR 200101790 T2 TR200101790 T2 TR 200101790T2 TR 2001/01790 T TR2001/01790 T TR 2001/01790T TR 200101790 T TR200101790 T TR 200101790T TR 200101790 T2 TR200101790 T2 TR 200101790T2
Authority
TR
Turkey
Prior art keywords
formula
pores
less
substance
penetrate
Prior art date
Application number
TR2001/01790T
Other languages
English (en)
Inventor
Cevc Gregor
Original Assignee
Idea Ag.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8167168&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200101790(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Idea Ag. filed Critical Idea Ag.
Publication of TR200101790T2 publication Critical patent/TR200101790T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Gözeneklerin ortalama çapinin ortalama nufuz eden madde çapindan çok daha küçük olmasi gerçegi de göz önünde tutularaktan, nufuz etme yetenegine bagli olarak, bir bariyerdeki gözeneklere nufuz edebilen moleküler düzenlemeleri kapsayan bir formül ile, nufuz eden maddeleri tasiyabilmelerini ya da gözeneklerden geçtikten sonra, formülün viskozitesinin artmasina yol açacak miktarda kivam verici maddelerden en az birini içeren ve kalinlasmaya yol açmayan karsilik gelen bir formülün azami 5 Nm/s hizla yayilmasi ve tutulma açisindan ise, uygulama alaninda bulunan ve/veya en az bir antioksidan maddenin oksidasyon endeksini neredeyse her 6 ayda bir ve/veya bakteriyel sayimi azaltacak miktarda formülde bulunan bir mikrop öldürücü maddenin, aerobik bakteriler için 100'den az, entero-bakteriler için 10 dan az ve Pseudomonas aureuginosa yada Staphilococcus aureus için 1 den az olacak sekilde, 4 gün içinde, formülün toplam kütlesinin beher graminda 1 milyon mikrop sayiminiDEVAMI VAR
TR2001/01790T 1998-12-23 1998-12-23 Yayılgan olmayan in vivo topik uygulamalar için geliştirilmiş formül TR200101790T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP1998/008421 WO2000038653A1 (en) 1998-12-23 1998-12-23 Improved formulation for topical non-invasive application in vivo

Publications (1)

Publication Number Publication Date
TR200101790T2 true TR200101790T2 (tr) 2001-10-22

Family

ID=8167168

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/01790T TR200101790T2 (tr) 1998-12-23 1998-12-23 Yayılgan olmayan in vivo topik uygulamalar için geliştirilmiş formül

Country Status (22)

Country Link
US (2) US7175850B2 (tr)
EP (1) EP1140021B1 (tr)
JP (1) JP2002533379A (tr)
KR (1) KR100638150B1 (tr)
CN (1) CN1320880C (tr)
AT (1) ATE272391T1 (tr)
AU (1) AU770803B2 (tr)
BR (1) BR9816113A (tr)
CA (1) CA2356080C (tr)
CZ (1) CZ20012038A3 (tr)
DE (1) DE69825495T2 (tr)
EE (1) EE200100342A (tr)
ES (1) ES2226203T3 (tr)
HK (1) HK1040629B (tr)
HR (1) HRP20010309B1 (tr)
HU (1) HUP0104424A3 (tr)
MX (1) MXPA01006424A (tr)
NO (1) NO20013164L (tr)
PL (1) PL193824B1 (tr)
RU (1) RU2207844C2 (tr)
TR (1) TR200101790T2 (tr)
WO (1) WO2000038653A1 (tr)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
HUP0102741A3 (en) * 1998-10-23 2002-12-28 Idea Ag Method for developing, testing and using associates of macromolecules and complex aggregates for improved payload and controllable de/association rates
CN1320880C (zh) * 1998-12-23 2007-06-13 伊迪亚股份公司 改进的体内局部无创伤用制剂
ES2173679T3 (es) 1999-01-27 2002-10-16 Idea Ag Inmunizacion/transporte transnasal con vehiculos altamente adaptables.
EP1031346B1 (en) 1999-01-27 2002-05-02 Idea Ag Noninvasive vaccination through the skin
MXPA02000053A (es) * 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
US20030077301A1 (en) * 1999-12-16 2003-04-24 Maibach Howard I. Topical pharmaceutical composition for the treatment of inflammatory dermatoses
JP2004504357A (ja) * 2000-07-26 2004-02-12 アルコン，インコーポレイテッド ポリマー性懸濁化剤を含有しない薬学的懸濁組成物
AU2002231697B2 (en) 2000-12-07 2006-09-07 Enceladus Pharmaceuticals B.V. Composition for treatment of inflammatory disorders
US8246969B2 (en) 2001-11-16 2012-08-21 Skinmedica, Inc. Compositions containing aromatic aldehydes and their use in treatments
US7763663B2 (en) 2001-12-19 2010-07-27 University Of Massachusetts Polysaccharide-containing block copolymer particles and uses thereof
EP1534213B1 (en) * 2002-03-13 2013-04-24 Sköld, Thomas Water-based delivery systems
US8367098B2 (en) 2002-04-30 2013-02-05 The Population Council, Inc. Unique combinations of antimicrobial compositions
EP1371362A1 (en) * 2002-06-12 2003-12-17 Universiteit Utrecht Holding B.V. Composition for treatment of inflammatory disorders
AU2003256381A1 (en) * 2002-07-03 2004-01-23 Pericor Science, Inc Compositions of hyaluronic acid and methods of use
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
MXPA05003744A (es) * 2002-10-11 2005-09-20 Idea Ag Agregado de deformabilidad aumentada, que comprende al menos tres anfipatos, para un transporte mejorado a traves de barreras semi-permeables y para la aplicacion de farmacos no invasivos en vivo, en especial a traves de la piel.
US7323443B2 (en) 2002-12-12 2008-01-29 Agennix Inc. Lactoferrin in the reduction of pain
WO2004103285A2 (en) * 2003-05-14 2004-12-02 Agennix Incorporated Lactoferrin in the treatment of diabetes mellitus
RU2371204C2 (ru) * 2003-09-22 2009-10-27 Инновейшн Текнолоджиз, Инк. Устройство и способ для промывания раны
FR2861304B1 (fr) * 2003-10-23 2008-07-18 Univ Grenoble 1 Modulateurs des canaux cftr
US8974774B2 (en) 2004-03-03 2015-03-10 Revance Therapeutics, Inc. Compositions and methods for topical diagnostic and therapeutic transport
US9211248B2 (en) 2004-03-03 2015-12-15 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
WO2005099715A2 (en) * 2004-04-08 2005-10-27 Retmed Pty Ltd. Treatment of ophthalmic conditions with mineralcorticoids
KR100772327B1 (ko) * 2004-04-22 2007-10-31 주식회사유한양행 하이드로코티손 또는 그 염을 함유하는 나노에멀젼 조성물
DE102004021992A1 (de) * 2004-05-03 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Topische Zubereitung enthaltend Ambroxol
US20050255154A1 (en) 2004-05-11 2005-11-17 Lena Pereswetoff-Morath Method and composition for treating rhinitis
US20080193393A1 (en) * 2004-09-24 2008-08-14 Lipo Chemicals Inc. Delivery System for Topically Applied Compounds
WO2006047744A2 (en) * 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof
US20080095722A1 (en) * 2004-11-12 2008-04-24 Idea Ag Extended Surface Aggregates in the Treatment of Skin Conditions
US20080214669A1 (en) * 2005-01-14 2008-09-04 Lipo Chemicals Inc. Composition and Method For Treating Hyperpigmented Skin
ZA200707352B (en) 2005-03-03 2009-04-29 Revance Therapeutics Inc Compositions and methods for topical application and transdermal delivery of botulinum toxins
JP5846711B2 (ja) 2005-06-09 2016-01-20 メダ アーベー 炎症性疾患の治療のための方法及び組成物
KR101430767B1 (ko) 2005-07-18 2014-08-19 유니버시티 오브 메사츄세츠 로웰 나노에멀젼 조성물 및 이의 제조 및 사용 방법
CA2620585C (en) * 2005-08-31 2015-04-28 Abraxis Bioscience, Llc Compositions comprising poorly water soluble pharmaceutical agents and antimicrobial agents
KR101643416B1 (ko) * 2005-08-31 2016-07-27 아브락시스 바이오사이언스, 엘엘씨 증가된 안정성을 가진 수 난용성 약물의 조성물 및 제조방법
CA2616515C (en) * 2005-09-01 2014-09-23 Biolipox Ab Antihistamine- and corticosteroid- containing liposome composition and its use for the manufacture of a medicament for treating rhinitis and related disorders
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US7998717B2 (en) 2005-12-02 2011-08-16 Pacific Biosciences Of California, Inc. Mitigation of photodamage in analytical reactions
US20070154403A1 (en) * 2006-01-05 2007-07-05 Thomas Skold Oral, Pulmonary and Transmucosal Delivery Composition
US9308181B2 (en) 2006-03-06 2016-04-12 Nuvo Research Inc. Topical formulations, systems and methods
US8343962B2 (en) 2006-03-06 2013-01-01 Nuvo Research Inc. Topical formulation
WO2007102090A2 (en) * 2006-03-06 2007-09-13 Fqubed Inc. Topical formulation
US9642912B2 (en) 2006-03-06 2017-05-09 Crescita Therapeutics Inc. Topical formulations for treating skin conditions
US7767217B2 (en) 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
WO2008020032A1 (en) * 2006-08-16 2008-02-21 Action Medicines, S.L. Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases
WO2008070538A2 (en) 2006-12-01 2008-06-12 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
JP5292304B2 (ja) 2006-12-01 2013-09-18 アンテリオス， インコーポレイテッド ペプチドナノ粒子およびその使用
PT2094331T (pt) * 2006-12-19 2016-11-14 Innovation Tech Inc Dispositivos e métodos para entregar agentes activos a locais-alvo
US20110097372A1 (en) * 2009-10-26 2011-04-28 Rucinski Paul J Devices, methods, and compositions for controlling infections
CN101032473B (zh) * 2007-04-05 2010-04-07 上海交通大学 三明治型药物缓释膜及其制备方法
KR20150028856A (ko) 2007-05-31 2015-03-16 안테리오스, 인코퍼레이티드 핵산 나노입자 및 이의 용도
KR101722038B1 (ko) 2007-07-26 2017-04-03 레반스 테라퓨틱스, 아이엔씨. 항미생물 펩티드, 조성물, 및 이용 방법
ITRM20070510A1 (it) * 2007-10-02 2009-04-03 Rmfa Trading S A Composizioni oftalmiche a base di polisaccaride del seme di tamarindo e acido ialuronico.
CN101951899B (zh) * 2008-01-18 2012-12-05 霍法格研究Ip(Mir)有限公司 异常眼内压治疗
KR101749032B1 (ko) 2008-05-28 2017-06-20 레베라겐 바이오파마 인코포레이티드 질환의 치료를 위한 ＮＦ-κＢ 의 비호르몬성 스테로이드 조절제
US8173147B2 (en) * 2008-08-15 2012-05-08 Xttrium Laboratories, Inc. Gentle, non-irritating, non-alcoholic skin disinfectant
NZ592300A (en) 2008-10-03 2013-01-25 Nexmed Holdings Inc Stabilized composition for treating psoriasis
ES2682075T3 (es) * 2009-06-03 2018-09-18 Sequessome Technology Holdings Limited Formulaciones para el tratamiento de dolor de tejido profundo
WO2011022707A1 (en) 2009-08-21 2011-02-24 Henk-Andre Kroon Vesicular formulations
WO2011127048A2 (en) 2010-04-05 2011-10-13 Validus Biopharma NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE
US8834847B2 (en) 2010-08-12 2014-09-16 Pacific Biosciences Of California, Inc. Photodamage mitigation compounds and systems
CA2817206C (en) * 2010-11-10 2020-03-10 Tengion, Inc. Injectable formulations for organ augmentation
EP2661264B1 (en) 2011-01-07 2018-12-05 Allergan, Inc. Melanin modification compositions and methods of use
RU2456979C1 (ru) * 2011-04-11 2012-07-27 Общество с ограниченной ответственностью "ЭкоБиоФармДубна" Индометацин на основе фосфолипидных наночастиц для применения в офтальмологии
CN104023717B (zh) * 2011-06-29 2017-08-04 阿维达斯制药有限责任公司 包括脂质微胶囊递送媒剂的局部调配物和其用途
CN102847151B (zh) * 2011-07-01 2014-08-13 天津金耀集团有限公司 含有巯乙基磺酸钠和糖皮质激素的吸入制剂及其制备方法
PT2782584T (pt) 2011-11-23 2021-09-02 Therapeuticsmd Inc Preparações e terapias de substituição para hormonoterapias naturais combinadas
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RU2477632C1 (ru) * 2011-12-22 2013-03-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Российский химико-технологический университет им. Д.И. Менделеева (РХТУ им. Д.И. Менделеева) Способ получения липосомальной формы биологически активного вещества
GB201205642D0 (en) 2012-03-29 2012-05-16 Sequessome Technology Holdings Ltd Vesicular formulations
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN102772396B (zh) * 2012-07-25 2013-12-18 杭州普瑞美克生物科技有限公司 用于动物抓咬伤后皮肤清洁抗菌且配合使用的组合型制剂
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN114949237A (zh) * 2013-07-31 2022-08-30 斯昆申技术控股有限责任公司 囊泡
US9309205B2 (en) * 2013-10-28 2016-04-12 Wincom, Inc. Filtration process for purifying liquid azole heteroaromatic compound-containing mixtures
EP3116986B1 (en) 2014-03-14 2023-07-05 GOJO Industries, Inc. Hand sanitizers with improved aesthetics and skin-conditioning to encourage compliance with hand hygiene guidelines
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
US9459201B2 (en) 2014-09-29 2016-10-04 Zyomed Corp. Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing
EP3247333B1 (en) 2015-01-20 2021-07-21 Tetraderm Group LLC Versatile topical drug delivery vehicle and multifactorial tissue moisturizer that provides mucosal and skin barrier restoration
WO2017004205A1 (en) 2015-06-29 2017-01-05 Reveragen Biopharma, Inc. NON-HORMONAL STEROID MODULATORS OF NF-κB FOR TREATMENT OF DISEASE
HRP20211669T1 (hr) 2015-06-30 2022-02-18 Sequessome Technology Holdings Limited Multifazni pripravci
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP6987039B2 (ja) 2015-08-24 2021-12-22 スミス アンド ネフュー インコーポレイテッド 抗菌剤と組み合わせた中極性油の細菌性バイオフィルムに対する相乗的抗菌活性
CN107477368A (zh) * 2015-09-11 2017-12-15 刘玉友 一种用于提高原油减阻剂抗剪切性能的添加剂
US20190000822A1 (en) * 2016-02-24 2019-01-03 Nicolae Arcasiu Chlorine or bromine salts of cetylpyridinium for use in the treatment of cutaneous and acute porphyrias and psoriasis
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
EP3538083B1 (en) 2016-11-14 2024-07-10 NeuVision Development LLC Formulations for the treatment of ocular surface diseases and related methods
EP3541358A1 (en) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermal delivery of large agents
CN107970257A (zh) * 2017-12-22 2018-05-01 成都博创必成医药技术有限公司 一种耳用药物组合物、制备方法及其应用与耳用药物制剂
CN112533478A (zh) * 2018-08-08 2021-03-19 3M创新有限公司 治疗组合物和相关方法
DE102018133374A1 (de) * 2018-12-21 2020-06-25 Gelita Ag Kollagenhydrolysat zur Verwendung gegen Hautkrankheiten und Darmkrankheiten
US11382922B2 (en) 2019-03-07 2022-07-12 Reveragen Biopharma, Inc. Aqueous oral pharmaceutical suspension compositions
CN111904932B (zh) * 2019-05-08 2023-06-20 北京德立福瑞医药科技有限公司 一种含有糖皮质激素的胶束制剂及其制备方法
CN114040766A (zh) 2019-07-01 2022-02-11 奥库里斯公司 用于稳定包含药物的水性组合物pH的方法
DE102019218241A1 (de) * 2019-11-26 2021-05-27 Beiersdorf Ag Wirkstoffkombinationen aus Ubichinol und Carrageenan und kosmetische oder dermatologische Zubereitungen, solche Wirkstoffkombinationen enthaltend
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN114831939B (zh) * 2021-01-30 2024-06-07 南京星银药业集团有限公司 一种醋酸曲安奈德组合物喷雾剂及其制备方法
CN113425845B (zh) * 2021-08-10 2022-12-02 成都倍特药业股份有限公司 一种预防和/或治疗脱发症的传递体制剂及其制备方法和用途
PL244294B1 (pl) * 2022-09-20 2024-01-03 Univ Medyczny W Lodzi Kompozycja farmaceutyczna do stosowania miejscowego oraz jej zastosowanie w leczeniu naczyniaków krwionośnych u dzieci

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55153713A (en) 1979-05-02 1980-11-29 Kureha Chem Ind Co Ltd Pharmaceutical preparation of ribosome containing active substance
CA1134276A (en) 1980-03-26 1982-10-26 Alec D. Keith Phosphatide-lower alkanolamine complex for topical application
JPS56135416A (en) 1980-03-27 1981-10-22 Mitsubishi Chem Ind Ltd Pharmaceutical preparation for skin
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
USRE33273E (en) 1982-08-18 1990-07-24 Georgia Tech Research Corporation Materials having improved nonfouling characteristics and method of making same
EP0152379A3 (de) 1984-02-15 1986-10-29 Ciba-Geigy Ag Verfahren zur Herstellung von pharmazeutischen Zusammensetzungen enthaltend unilamellare Liposomen
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
GB8501015D0 (en) 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
JPS61271204A (ja) 1985-05-27 1986-12-01 Shiseido Co Ltd リポソ−ム製剤
IL79114A (en) 1985-08-07 1990-09-17 Allergan Pharma Method and composition for making liposomes
EP0238554A4 (en) 1985-09-27 1987-10-27 Univ California LIPOSOME SYSTEM FOR TRANSDERMAL DRUG ADMINISTRATION.
JPS6295134A (ja) * 1985-10-21 1987-05-01 Nippon Saafuakutanto Kogyo Kk リポソ−ムの製造法
DE3542773A1 (de) 1985-12-04 1987-06-11 Roehm Pharma Gmbh Hautwirksame pharmaka mit liposomen als wirkstofftraeger
FR2597367B1 (fr) 1986-04-22 1988-07-15 Oreal Procede pour faciliter la formation de spherules lipidiques en dispersion dans une phase aqueuse et pour ameliorer leur stabilite et leur taux d'encapsulation, et dispersions correspondantes.
DK86988A (da) 1987-02-25 1988-08-26 Takeda Chemical Industries Ltd Liposompraeparat og anvendelse deraf
CA1323306C (en) 1987-03-05 1993-10-19 Mircea C. Popescu Pharmacological agent-lipid solution preparation
US4911928A (en) 1987-03-13 1990-03-27 Micro-Pak, Inc. Paucilamellar lipid vesicles
US4855090A (en) 1987-03-13 1989-08-08 Micro-Pak, Inc. Method of producing high aqueous volume multilamellar vesicles
US4828837A (en) 1987-03-30 1989-05-09 Liposome Technology, Inc. Non-crystalline minoxidil composition, its production and application
US4783450A (en) 1987-04-13 1988-11-08 Warner-Lambert Company Use of commercial lecithin as skin penetration enhancer
US5238613A (en) 1987-05-20 1993-08-24 Anderson David M Microporous materials
IL86650A0 (en) 1987-06-30 1988-11-30 Biophor Corp Animal derived cells and liposomes,having an antigenic protein incorporated into their membrane
US4937078A (en) 1988-08-26 1990-06-26 Mezei Associates Limited Liposomal local anesthetic and analgesic products
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
US5064655A (en) 1989-02-24 1991-11-12 Liposome Technology, Inc. Liposome gel composition and method
JPH0334920A (ja) 1989-04-21 1991-02-14 Otsuka Pharmaceut Co Ltd リポソームに結合及至組合わされた生物活性化合物及びそれを含有する医薬
ATE104862T1 (de) * 1989-08-03 1994-05-15 Hisamitsu Pharmaceutical Co Hautcremezubereitung zur aeusserlichen verwendung.
WO1991004013A1 (en) 1989-09-21 1991-04-04 Micro Vesicular Systems, Inc. Hybrid paucilamellar lipid vesicles
CA2067754C (en) * 1990-08-24 2002-06-04 Gregor Cevc Preparation for the application of agents in mini-droplets
SE9003100D0 (sv) 1990-09-28 1990-09-28 Kabivitrum Ab Lipid formulation system
JP2922017B2 (ja) 1991-03-25 1999-07-19 第一製薬株式会社 経口用脂質膜構造体
ATE126434T1 (de) 1991-06-10 1995-09-15 Sanol Arznei Schwarz Gmbh Nitroglycerin-pflaster und verfahren zu seiner herstellung.
SE9200952D0 (sv) 1992-03-27 1992-03-27 Kabi Pharmacia Ab Pharmaceutical carrier system containing defined lipids
SE9200951D0 (sv) 1992-03-27 1992-03-27 Kabi Pharmacia Ab Pharmaceutical composition containing a defined lipid system
DE4336557C2 (de) 1993-05-06 1997-07-17 Lohmann Therapie Syst Lts Estradiolhaltiges transdermales therapeutisches System, Verfahren zu seiner Herstellung und seine Verwendung
FR2714601B1 (fr) 1993-12-30 1996-02-09 Oreal Composition dépigmentante pour le traitement simultané des couches superficielles et profondes, son utilisation.
US5536263A (en) 1994-03-30 1996-07-16 Lectec Corporation Non-occulusive adhesive patch for applying medication to the skin
US5540934A (en) 1994-06-22 1996-07-30 Touitou; Elka Compositions for applying active substances to or through the skin
DE19536244A1 (de) 1994-09-30 1996-04-04 Juergen Dr Regenold Pharmazeutische Zusammensetzung zur lokalen Applikation
IT1270678B (it) 1994-10-20 1997-05-07 Bayer Ag Liposomi al chetoprofen
DE4447287C1 (de) * 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US20020048596A1 (en) 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
DE19512181C2 (de) 1995-03-31 2003-11-06 Hexal Pharma Gmbh Transdermales System mit Ramipril und/oder Trandolapril als ACE-Hemmer
WO1997021428A1 (de) 1995-12-12 1997-06-19 Vesifact Ag Cortisolspray zur topischen verabreichung
US5837289A (en) 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
DK0937155T3 (da) 1996-08-09 2005-01-31 Keygene Nv Resistens over for nematoder og/eller bladlus
IL128632A (en) 1996-08-22 2003-03-12 Rtp Pharma Corp Compositions comprising microparticles of water-insoluble substances and method for preparing same
AU5777498A (en) 1997-01-13 1998-08-03 Cilag A.G. Liposome-based topical tretinoin formulation
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
US6274634B1 (en) 1997-05-14 2001-08-14 Senju Pharmaceutical Co., Ltd. Aqueous suspension preparations with excellent redispersibility
US5985379A (en) * 1997-07-22 1999-11-16 Franklin Mint Company Decorative display plate
DK1143958T3 (da) 1998-09-03 2007-04-10 Univ Loma Linda Med Farmaceutisk sammensætning med og anvendelse af R-NSAID til bekæmpelse af betændelser
CN1320880C (zh) 1998-12-23 2007-06-13 伊迪亚股份公司 改进的体内局部无创伤用制剂
ES2173679T3 (es) 1999-01-27 2002-10-16 Idea Ag Inmunizacion/transporte transnasal con vehiculos altamente adaptables.
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
MXPA02000053A (es) 1999-07-05 2003-07-21 Idea Ag Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
US6582724B2 (en) 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
US6586000B2 (en) 1999-12-16 2003-07-01 Dermatrends, Inc. Hydroxide-releasing agents as skin permeation enhancers
US6562370B2 (en) 1999-12-16 2003-05-13 Dermatrends, Inc. Transdermal administration of steroid drugs using hydroxide-releasing agents as permeation enhancers
US6645520B2 (en) 1999-12-16 2003-11-11 Dermatrends, Inc. Transdermal administration of nonsteroidal anti-inflammatory drugs using hydroxide-releasing agents as permeation enhancers
JP2004504357A (ja) 2000-07-26 2004-02-12 アルコン，インコーポレイテッド ポリマー性懸濁化剤を含有しない薬学的懸濁組成物
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition

Also Published As

Publication number Publication date
HK1040629B (zh) 2005-01-28
HRP20010309B1 (en) 2005-06-30
NO20013164L (no) 2001-08-22
PL349467A1 (en) 2002-07-29
CZ20012038A3 (cs) 2001-09-12
ATE272391T1 (de) 2004-08-15
KR100638150B1 (ko) 2006-10-26
CN1327382A (zh) 2001-12-19
EE200100342A (xx) 2002-10-15
EP1140021B1 (en) 2004-08-04
BR9816113A (pt) 2001-10-23
KR20010107991A (ko) 2001-12-07
ES2226203T3 (es) 2005-03-16
HRP20010309A2 (en) 2002-06-30
AU770803B2 (en) 2004-03-04
EP1140021A1 (en) 2001-10-10
JP2002533379A (ja) 2002-10-08
NO20013164D0 (no) 2001-06-22
CA2356080A1 (en) 2000-07-06
MXPA01006424A (es) 2002-06-04
PL193824B1 (pl) 2007-03-30
US20070184114A1 (en) 2007-08-09
DE69825495T2 (de) 2005-07-28
CN1320880C (zh) 2007-06-13
AU2513799A (en) 2000-07-31
US7175850B2 (en) 2007-02-13
RU2207844C2 (ru) 2003-07-10
HK1040629A1 (en) 2002-06-21
HUP0104424A2 (hu) 2002-03-28
US20020064524A1 (en) 2002-05-30
CA2356080C (en) 2009-05-12
HUP0104424A3 (en) 2002-12-28
WO2000038653A1 (en) 2000-07-06
DE69825495D1 (de) 2004-09-09

Similar Documents

Publication Publication Date Title
TR200101790T2 (tr) Yayılgan olmayan in vivo topik uygulamalar için geliştirilmiş formül
Fine et al. Effects of sublethal exposure to an antiseptic mouthrinse on representative plaque bacteria
BR9707739A (pt) Utilizacão de compostos orgânicos
BR9406507A (pt) Composição de combustivel ou de lubrificante polt-1-n-alquenaminas e aplicação das mesmas
TNSN06205A1 (fr) Utilisation d'un lyophilisat de cellules végétales dédifférenciées afin de dépigmenter et/ou d'éclaircir la peau
AU6247299A (en) Topical dermal antimicrobial compositions
TR200101339T2 (tr) Potasyum kanal modülatörleri olarak 3-yer-alanlı-4-arilkinolin-2-on türevleri, 3,4-okzadiazolon türevleri
Papini et al. Wound management in burn centres in the United Kingdom
ATE193973T1 (de) Gegen zahnbelag, gingivitis und karies wirkende orale zusammensetzung
BR9801044A (pt) Composições antiácidas lìquidas.
TR199800244T2 (tr) Griseofulvinin, kanserlerin ilerlemesini önlemede kullanimi.
KR860001524A (ko) 요오도퍼 조성물
DE60114272D1 (de) Verwendung von spezifischen Fettstoffen zur Modifizierung der physico-chemischen Eigenschaften der Haut und/oder der Schleimhaut als Mittel zur Verhinderung oder Reduzierung der Adhäsion von Mikro-organismen darauf
KR970032795A (ko) 요산 및 요산 분해 효소의 유효 함량을 함유하는 화장용 및 피부 관리용 조성물
KR910005846A (ko) 치약 조성물
Cowen Relative merits of cin use’and laboratory methods for the evaluation of antimicrobial products
ATE195055T1 (de) Insektizide zusammensetzung die diatomeenerde und siliziumdioxid enthalten
FR2592654A1 (fr) Composition antifriction autolubrifiante.
AR032356A1 (es) Formulacion mejorada para aplicaciones topicas no invasivas in vivo
ATE359826T1 (de) Vorbeugung der kronischen transplantat-abstossung durch eine kombination von immuntoxinen und kostimulationblocker
BR0214538A (pt) Prevenção de crescimento microbiano em fluidos para trabalho com metal
CN1053727A (zh) 抗菌剂
Costa et al. The role of saliva in the persistence of Streptococcus gordonii in water
EP1270973A3 (en) High speed rolling bearing
KR930000106A (ko) 항균성 유아용 분말조성물